Xiansheng Pharmaceutical Group announced today that its self-developed monoclonal antibody targeting the interleukin-2 receptor beta chain long-acting antagonist sIM0725 has been approved by the China Drug Administration to conduct clinical trials in China and is intended to be used to treat autoimmune diseases.

Zhitongcaijing · 2d ago
Xiansheng Pharmaceutical Group announced today that its self-developed monoclonal antibody targeting the interleukin-2 receptor beta chain long-acting antagonist sIM0725 has been approved by the China Drug Administration to conduct clinical trials in China and is intended to be used to treat autoimmune diseases.